Alta-innovations news

NewsRSS FeedAtom Feed

PSIOXUS THERAPEUTICS INITIATES SECOND CLINICAL STUDY OF ONCOLYTIC VACCINE

Description
PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, will initiate a clinical trial of ColoAd1, a systemically available oncolytic vaccine, to compare the effectiveness of direct intra-tumoral injection with intravenous injection in patients with non-metastatic colorectal cancer
Date:
24/06/2013

Irresistible Materials secures funding boost and new Chairman

Description
Irresistible Materials (IM), a UK materials technology company spun-out from the University of Birmingham, is pleased to announce £290,000 of further support from its investing shareholder (Mercia Fund Management) and new business angels from the US and UK, coupled with the appointment of Stuart McIntosh as its new Chairman.
Date:
20/05/2013

New appointment at PsiOxus Therapeutics

Description
OXFORD, UK – 8th May 2013 – PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced that Dr. Christine Wilkinson Blanc has joined the company's management team as Chief Medical Officer.
Date:
17/05/2013

Serascience launches world's first point-of-care diagnostic device for multiple myeloma

Description
Serascience Limited, a specialist cancer diagnostics company, announces the launch of SeraliteTM, its proprietary point-of-care diagnostic device for multiple myeloma. The device will initially be available for research use only, followed by CE marking and application for FDA approval.
Date:
15/04/2013

Native Antigen Company receives funding boost

Description
Oxford-based The Native Antigen Company (NAC) has received new investment from the Mercia Growth Fund 1 and NAC's existing shareholders.
Date:
02/04/2013

University of Birmingham Spinout Company is developing a novel drug for the treatment of Glaucoma

Description
Scientists at the University of Birmingham have received funding from the Technology Strategy Board, the UK's innovation agency, to develop a novel multi action siRNA drug with proven neuroprotective and neuroregenerative activity to treat Glaucoma.
Date:
20/03/2013

PsiOxus Therapeutics Completes Patient Enrollment for Phase II Wasting Disease Therapeutic MT-102

Description
PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia.
Date:
04/03/2013

University of Birmingham scientists devise unique stroke assessment tool

Description
Scientists at the University of Birmingham have devised a unique screening instrument that provides a 'one-stop' brain function profile of patients who have suffered stroke or other neurological damage.
Date:
16/01/2013
Displaying 21 to 30 of 40